Company intelligence / Profile preview

WindMIL Therapeutics

Baltimore, Maryland, United Stateswindmiltx.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Currently conducting a Phase 2 clinical trial assessing MILs-NSCLC in combination with nivolumab for patients with locally advanced unresectable or metastatic non-small cell lung cancer who are refractory to or have relapsed on an anti-PD-1-containing regimen. First patient in the combination therapy portion was recently dosed at Sarah Cannon Research Institute.

Therapeutic areas: Oncology
Modalities: Cell therapyMarrow-infiltrating lymphocytes (MILs)Adoptive cell therapy
Industry: Biotech

Drug pipeline

3 assets

marrow-infiltrating lymphocytes

2 more assets in the full pipeline.

Partnerships

Bristol Myers Squibb CompanyCognate BioServicesUniversity of Pennsylvania

Beyond the preview

Go deeper on WindMIL Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WindMIL Therapeutics.